Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

NCT ID: NCT02639520

Last Updated: 2017-07-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 659 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2017-06-29

Brief Summary

To demonstrate non-inferiority of a non-antibiotic therapy with CLR versus an antibiotic treatment with fosfomycin trometamol in women suffering from acute lower uUTIs as measured by the proportion of patients who received an additional antibiotic treatment for acute lower uUTIs during the trial.

Detailed Description

The trial is designed as a comparison of two different modes of action in order to look for alternatives to antibiotic treatment of uncomplicated UTIs. Treatment with CLR is a nonantibiotic therapy and is compared to an antibiotic treatment. Thus, the trial aim is to reduce antibiotics use and moreover to reduce the pressure of developing bacterial resistance against antibiotics due to widespread use, which is an additional advantage of the CLR therapy.

The trial results are expected to demonstrate that antibiotic prescriptions in women for treatment of lower uUTIs can be reduced by an alternative and safe non-antibiotic treatment.

Conditions

Urinary Tract Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Group Canephron® N

Canephron® N \& fosfomycin trometamol-placebo

Group Type: ACTIVE_COMPARATOR

Canephron® N

Intervention Type: DRUG

2 tablets 3 times a day for 7 days

Fosfomycin trometamol-placebo

Intervention Type: DRUG

1 sachet of 8 g of granules; one single dose on Day 1

Group Fosfomycin Trometamol

Canephron® N-placebo \& fosfomycin trometamol

Group Type: ACTIVE_COMPARATOR

Fosfomycin trometamol

Intervention Type: DRUG

1 sachet of 8 g of granules; one single dose on Day 1

Canephron® N-placebo

Intervention Type: DRUG

2 tablets 3 times a day for 7 days

Interventions

Canephron® N

2 tablets 3 times a day for 7 days

Intervention Type: DRUG

Fosfomycin trometamol

1 sachet of 8 g of granules; one single dose on Day 1

Intervention Type: DRUG

Canephron® N-placebo

2 tablets 3 times a day for 7 days

Intervention Type: DRUG

Fosfomycin trometamol-placebo

1 sachet of 8 g of granules; one single dose on Day 1

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent (IC) and data protection declaration

2. Female outpatients aged 18 to 70 years

3. Sum-score of the main uUTI symptoms (dysuria, pollakisuria, and urgency) reported on the Acute Cystitis Symptom Score (ACSS)-"Typical" domain at Visit 1 is ≥6

4. Symptoms of the acute episode of lower uUTI are developed within not more than 6 days prior to Visit 1

5. Leukocyturia at Visit 1, confirmed by positive dipstick

6. Patients willing to refrain from consuming prohibited concomitant medications and products

7. Non-lactating female patients who are surgically sterile (have had a documented sterilization, bilateral oophorectomy at least 3 months before the start of the trial and/or hysterectomy), or postmenopausal (cessation of menses for at least 12 months), or women of childbearing potential with a negative pregnancy test at Visit 1 willing to use highly effective (failure rate less than 1% per year, i.e., Pearl Index <1) contraception methods, e.g., contraceptive patch, oral, injected or implanted hormonal methods of contraception, during the trial including the follow-up period.

Exclusion Criteria

1. Any signs of complicated urinary tract infections (UTIs), pyelonephritis (i.e., fever T ≥38.0°C [grade 2], flank and/or back pain, chills and shivers), and/or vulvo-vaginitis with vaginal and/or with urethral discharge (without urination) at Visit 1.

2. Any conditions that may lead to complicated infections (i.e., renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, uncontrolled diabetes mellitus, spinal cord injury, etc.).

3. Chronic infection of the urinary tract known from medical history.

4. Persisting signs or symptoms of severe, progressive, or uncontrolled systemic disease (i.e., renal, hepatic, biliary, hematological, gastro-intestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease).

5. Uncontrolled hypertension (a diastolic blood pressure >95 mmHg at Visit 1).

6. Known severe cardiac insufficiency, coronary heart disease, valvular heart disease, cardiac arrhythmia, QT interval prolongation or other severe cardiac disease at Visit 1.

7. Any antibiotic therapy within 30 days prior to Visit 1.

8. Other acute infections (except uUTIs) requiring antibiotic treatment at Visit 1.

9. Patients receiving treatment for suspected or confirmed UTI (antibiotic or phytopharmaceutical) within 30 days prior to Visit 1.

10. Patients who took anti-inflammatory drugs (e.g., ibuprofen) or spasmolytics for any reason within 24 hours prior to Visit 1, and/or are not willing to stop the intake of any of the medication not permitted for use during the trial.

11. Known severe impaired renal function (creatinine clearance <20 mL/min).

12. Active peptic ulcers.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Bionorica SE

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Florian Wagenlehner, Prof.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Gießen und Marburg GmbH

Locations

Justus-Liebig-Universität

Giessen, Hesse, Germany

Countries

Germany

References

Wagenlehner FM, Abramov-Sommariva D, Holler M, Steindl H, Naber KG. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int. 2018;101(3):327-336. doi: 10.1159/000493368. Epub 2018 Sep 19.

Reference Type: DERIVED

PMID: 30231252 (View on PubMed)

Other Identifiers

CanUTI-7

Identifier Type: -

Identifier Source: org_study_id